MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Tempus AI CEO Sales: Strategic De-Risking Amidst Rising Stakes

1 hour ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Tempus AI's Post-Acquisition Dip: A Strategic Entry Amidst Short-Term Volatility

1 week ago

Josh Gottheimer's Quiet Divestment: De-Risking Amidst Tech Advocacy

3 weeks ago

Bayer's Ruveon Move: De-Risking the Path to a Breakup and Shareholder Value

3 weeks ago

Heck Capital's Gold Retreat: De-Risking from Volatility, Not Abandoning the Haven

2 weeks ago

Cathie Wood's Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks

Tempus AI shares fell ~6% Monday, extending YTD losses to 16%, after announcing a $1.5B all-stock acquisition of Personalis that raises dilution concerns ahead of July 30 earnings.

TEM

Stock News•1 months ago

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

AstraZeneca CEO Pascal Soriot said AI is accelerating drug development and improving clinical trial success odds, via partnerships with Tempus AI and Pathos.

AZN

Stock News•1 months ago

Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript

Tempus AI (TEM) held its Analyst/Investor Day to outline long-term strategic goals and operational updates. The event provided insights into the company's data-driven platform and future growth initia...

TEM

Stock News•2 months ago

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Tempus AI and Bristol Myers Squibb expanded their strategic collaboration to optimize clinical trial designs across five oncology and neuroscience programs. The initiative leverages Tempus' Lens platf...

BMY